Comparing of Minerva Neurosciences Inc. (NERV) and DBV Technologies S.A. (NASDAQ:DBVT)

Minerva Neurosciences Inc. (NASDAQ:NERV) and DBV Technologies S.A. (NASDAQ:DBVT), both competing one another are Biotechnology companies. We will contrast their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Minerva Neurosciences Inc. 7 0.00 N/A -1.38 0.00
DBV Technologies S.A. 9 0.00 N/A -3.27 0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 shows us the net margins, return on assets and return on equity of both companies.

Net Margins Return on Equity Return on Assets
Minerva Neurosciences Inc. 0.00% -56.4% -36.9%
DBV Technologies S.A. 0.00% 0% 0%

Analyst Recommendations

The Ratings and Recommendations for Minerva Neurosciences Inc. and DBV Technologies S.A. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Minerva Neurosciences Inc. 0 0 2 3.00
DBV Technologies S.A. 0 0 1 3.00

The upside potential is 150.00% for Minerva Neurosciences Inc. with consensus price target of $20. On the other hand, DBV Technologies S.A.’s potential upside is 36.59% and its consensus price target is $14. The information presented earlier suggests that Minerva Neurosciences Inc. looks more robust than DBV Technologies S.A. as far as analyst opinion.

Institutional & Insider Ownership

The shares of both Minerva Neurosciences Inc. and DBV Technologies S.A. are owned by institutional investors at 90.8% and 46.27% respectively. Insiders held 0.7% of Minerva Neurosciences Inc. shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Minerva Neurosciences Inc. 3.11% 16.29% -8.16% 5.4% -15.95% -1.48%
DBV Technologies S.A. -6.24% 9.23% -0.94% 41.55% -46.5% 47.51%

For the past year Minerva Neurosciences Inc. had bearish trend while DBV Technologies S.A. had bullish trend.


DBV Technologies S.A. beats Minerva Neurosciences Inc. on 4 of the 7 factors.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The companyÂ’s lead product candidate includes MIN-101, a compound for the treatment of patients with schizophrenia that completed Phase IIb clinical trial. It also offers MIN-202, which completed Phase IIa clinical trial for treating primary insomnia, as well as completed Phase 1b used for the treatment of major depressive disorder; and MIN-117, a compound that completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder. The companyÂ’ preclinical stage product includes MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of ParkinsonÂ’s disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which is in Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow’s milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen’s egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage product development programs include treatments for Crohn’s disease and respiratory syncytial virus. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.